Prevalence and molecular analysis of glucose-6-phosphate dehydrogenase deficiency in Chin State, Myanmar

Parasites Hosts Dis. 2023 May;61(2):154-162. doi: 10.3347/PHD.23004. Epub 2023 May 23.

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is caused by X-linked recessive disorderliness. It induces severe anemia when a patient with G6PD deficiency is exposed to oxidative stress that occurs with administration of an antimalarial drug, primaquine. The distribution of G6PD deficiency remains unknown while primaquine has been used for malaria treatment in Myanmar. This study aimed to investigate the prevalence of G6PD deficiency and its variants in Chin State, Myanmar. Among 322 participants, 18 (11 males and 7 females) demonstrated a G6PD deficiency. Orissa variant was dominant in the molecular analysis. This would be related to neighboring Indian and Bangladeshi population, in which Orissa variant was also reported as the main mutation type. The screening test for G6PD deficiency before primaquine treatment appears to be important in Myanmar.

Keywords: Chin State; Glucose-6-phosphate dehydrogenase deficiency; Myanmar; variant.

MeSH terms

  • Female
  • Glucosephosphate Dehydrogenase Deficiency* / epidemiology
  • Humans
  • Male
  • Myanmar / epidemiology
  • Prevalence
  • Primaquine / adverse effects
  • Primaquine / therapeutic use

Substances

  • Primaquine